Search Results

Anika Therapeutics, Inc. (NASDAQ: ANIK) today announced it is highlighting recently-launched products in high growth segments of joint preservation and restoration from its Regenerative Solutions, Sports Medicine and Arthrosurface Joint Solutions businesses during the 2024 American Academy of Orthopedic Surgeons (AAOS) Annual Meeting on February 13-15 in San Francisco, CA.

Arthrosurface®, Inc., a global leader in joint preservation technology, recently received 510K clearance from the FDA for its BOSS™ Toe Fixation System.

Arthrosurface®, Inc. announced today the official launch of its latest product, the stemless OVOMotion™ Shoulder Arthroplasty System with Inlay Glenoid.

Arthrosurface, Inc. announces their recent FDA 510(k) Clearance to market the Patellofemoral (PF) WaveKahuna Arthroplasty System.

Arthrosurface® announced today that The Company received FDA 510(k) Clearance to market the OVOMotion™ Shoulder Arthroplasty System.

Arthrosurface, Inc. announced that midterm clinical results reconfirmed joint preservation in patellofemoral (PF) surgery with the PF Wave™ Implant System.

ArthroSurface announced today that it has completed the acquisition of an acellular dermal stabilization device technology, including the intellectual property rights to and associated with this technology, from WASAS, LLC.

Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated joint preservation and regenerative therapies company with products leveraging its proprietary hyaluronic acid (HA) technology platform, today announced it has signed agreements to acquire Parcus Medical,